Table 1. Characteristics of the patients.
| Variable | RP group n = 29 | Non-RP group n = 113 | p value | ||
|---|---|---|---|---|---|
| Age, yrs | 64±10 | 66±11 | 0.24 | ||
| Gender, female | 2 (6.9%) | 24 (21.2%) | 0.07 | ||
| BMI, kg/m 2 | 24.7±3.3 | 24.4±3.6 | 0.63 | ||
| Coronary risk factors | |||||
| Hypertension | 17 (58.6%) | 73 (64.6%) | 0.53 | ||
| Diabetes mellitus | 8 (27.6%) | 35 (31.0%) | 0.72 | ||
| Dyslipidemia | 11 (37.9%) | 39 (34.5%) | 0.73 | ||
| Smoking | 25 (86.2%) | 79 (69.9%) | 0.08 | ||
| Family history of CVD | 6 (20.7%) | 20 (17.7%) | 0.71 | ||
| Prior MI | 1 (3.5%) | 8 (7.1%) | 0.44 | ||
| Prior PCI | 0 (0.0%) | 8 (7.8%) | 0.14 | ||
| Clinical presentation | 0.96 | ||||
| STEMI | 22 (75.9%) | 83 (73.5%) | |||
| NSTEMI | 6 (20.7%) | 26 (23.0%) | |||
| UAP | 1 (3.5%) | 4 (3.5%) | |||
| Peak CK, U/L | 2295±1937 | 2280±2376 | 0.68 | ||
| Ejection fraction, % | 49.0±11.0 | 52.3±10.8 | 0.09 | ||
| Medications | On admission | At follow-up | On admission | At follow-up | |
| Statin | 8 (27.6%) | 29 (100%) | 29 (25.7%) | 111 (98.2%) | 0.83 |
| Ezetimibe | 0 (0.0%) | 4 (13.8%) | 4 (3.6%) | 9 (8.0%) | 0.3 |
| EPA | 0 (0.0%) | 2 (6.9%) | 5 (4.4%) | 7 (6.2%) | 0.25 |
| Fibrate | 3 (10.4%) | 2 (6.9%) | 7 (6.2%) | 1 (0.9%) | 0.46 |
Data are expressed as mean±standard deviation (SD) or number (%). Abbreviations: BMI, body mass index; CVD, cardiovascular disease; CK, creatine kinase; EPA, eicosapentaenoic acid; PCI, percutaneous coronary intervention; MI, myocardial infarction; NSTEMI, non-ST-segment elevation myocardial infarction; RP, rapid progression; STEMI, ST-segment elevation myocardial infarction; UAP, unstable angina pectoris.